Update (June 11, 2026): Bedinvetmab Improves Activity and Body Composition in Obese Dogs with Osteoarthritis

TL;DR

An April 2026 randomized, double-blind, placebo-controlled trial in obese dogs with osteoarthritis found that bedinvetmab improved objective activity and pain while preserving thigh muscle and reducing estimated body fat, with no adverse effects reported.

What just dropped

Phongphuwanan and colleagues published "Efficacy of bedinvetmab on pain, activity, and body composition in obese dogs with osteoarthritis: A randomized double-blind placebo-controlled trial" in Veterinary World (25 April 2026; DOI 10.14202/vetworld.2026.1595-1610). This is one of the first randomized trials to evaluate an anti-nerve-growth-factor monoclonal antibody specifically in the obese osteoarthritis population, which most prior bedinvetmab studies either excluded or did not stratify.

• A 56-day prospective, randomized, double-blind, placebo-controlled trial enrolled 28 client-owned obese dogs (body condition score 7/9 or higher) diagnosed with osteoarthritis, allocated to bedinvetmab or placebo by subcutaneous injection (Veterinary World, see reference 1 for dosing).
• Daily activity, measured as mean accelerometer-derived activity count per day (MAC/day), increased significantly over time, rising 25.6 percent from baseline by day 56 (p equals 0.032).
• Total pain scores on the Canine Brief Pain Inventory decreased significantly, with a mean reduction of 1.95 points (p less than 0.001), and a moderate negative correlation linked higher activity to lower pain (r equals -0.519, p less than 0.001).
• Body weight did not change significantly, but the treatment group showed a significant reduction in estimated body fat percentage and preservation of thigh muscle mass versus placebo. No adverse effects were reported.

Context

Obesity and osteoarthritis frequently coexist in dogs and reinforce each other through a cycle of pain, reduced activity, and muscle loss. Standard management pairs weight control with pharmacological analgesia, but NSAIDs carry gastrointestinal, renal, and hepatic risks that are of particular concern in older, overweight patients. Bedinvetmab, an anti-nerve-growth-factor monoclonal antibody, offers targeted analgesia and has compared favourably with NSAIDs on tolerability: in a separate randomized open-label study comparing bedinvetmab to meloxicam in 101 dogs with osteoarthritis, both treatments produced significant reductions in the Canine Orthopaedic Index, but the bedinvetmab group reported far fewer adverse events (4 versus 17, nine of them gastrointestinal) and more dogs completed the study (Walton-style head-to-head; reference 2).

The obese-dog trial extends this safety theme into a population where activity and body composition matter clinically: by relieving pain, bedinvetmab was associated with more movement and a more favourable body-composition profile even without meaningful weight loss.

What this changes in the Bedinvetmab (Librela) evergreen

The bedinvetmab adverse-events page (https://www.thevoyage.ai/forvets/knowledge/bedinvetmab-librela-adverse-events-dogs) summarises the drug's neurological safety profile and field-study efficacy. This trial adds a targeted population - obese dogs - in which bedinvetmab improved objective accelerometer activity (MAC/day up 25.6 percent, p equals 0.032) and owner-reported pain (CBPI down 1.95 points, p less than 0.001) while preserving thigh muscle and reducing body fat percentage, with no adverse effects reported in this small cohort. The favourable tolerability echoes the head-to-head comparison against meloxicam, where bedinvetmab generated fewer adverse events than the NSAID. The study is small (28 dogs) and short (56 days), so it should be read as a supportive signal in a high-risk group rather than definitive evidence; dosing should follow the current product label.

References

1. Phongphuwanan A, Tabtieang SP, Thanaboonnipat C, et al. Efficacy of bedinvetmab on pain, activity, and body composition in obese dogs with osteoarthritis: A randomized double-blind placebo-controlled trial. Veterinary World. 2026;19(4):1595-1610. https://veterinaryworld.org/Vol.19/April-2026/16.php
2. Frontiers in Veterinary Science. A randomised, parallel-group clinical trial comparing bedinvetmab to meloxicam for the management of canine osteoarthritis. Front Vet Sci. 2025;12:1502218. https://www.frontiersin.org/journals/veterinary-science/articles/10.3389/fvets.2025.1502218/full

Voyage Clinical Desk

From clinical question to SOAP draft - cited differentials, live dose calculators, owner handouts. Trained on the veterinary canon (Plumb's, Ettinger, JVIM, ACVIM consensus, 50,000+ indexed references). First answer free, no signup.

Open Voyage Clinical Desk: https://www.thevoyage.ai/forvets/ask?context=update-2026-06-11-bedinvetmab-obese-dogs-oa

Changelog

• 2026-06-11: First published.

Related reads

• Bedinvetmab (Librela) Adverse Events in Dogs: Neurological Safety Profile
• Grapiprant (Galliprant) for Canine Osteoarthritis Pain: EP4 Antagonism and Clinical Evidence